Annual testosterone screening for troops divides medical experts

Defense Secretary Pete Hegseth announced that testosterone deficiency screening will become part of the annual physical exam for service members. For those under thirty, the test is elective. If a deficiency is identified and treatment is recommended, testosterone replacement therapy (TRT) is at the individual’s discretion.

What doctors are pushing back on

The announcement has divided the medical field. Reactions range from ‘promising’ to ‘crazy’. Critics argue that low testosterone in otherwise healthy men of that age is rarely clinically relevant and that mass screening risks overtreatment. They also note the absence of evidence that TRT improves combat readiness in men without recognised hypogonadism.

Proponents point to the relationship between testosterone levels, muscle mass, recovery from physical exertion and mental resilience. In men, testosterone declines on average with age, a process sometimes called late-onset hypogonadism. This is a recognised condition, but the boundary between normal variation and clinically relevant deficiency remains contested.

Testosterone and aging

For longevity science, testosterone is a relevant hormone: it plays a role in muscle preservation, bone density, metabolism and possibly cognitive function in later life. Studies of TRT in older men show mixed results. Some demonstrate benefits for muscle mass and bone density. Others point to potential cardiovascular risks in certain subgroups. There is no consensus on broad preventive use of TRT.

The measure is a policy decision, not based on new clinical findings. It nonetheless raises a broader question that also runs through the longevity field: when does hormonal decline with aging represent a treatment indication, and when is it normal biology?

Read the original article